As of 2024, the forecast for Modulators of the Genital System and Sex Hormones sales in Canada indicates a gradual decline over the five-year forecast period from 2024 to 2028. Starting from 578.4 million USD in 2024, the sales are expected to decrease to 570.2 million USD by 2028.
The year-on-year percentage changes suggest a consistent slight downturn, reflecting a reduction in demand or potential market saturation. Compared to previous actual data, this trend highlights an ongoing challenge in sustaining market growth within this segment beyond 2023. The compound annual growth rate (CAGR) over the next five years is indicative of a modest decline.
Future trends to watch for include:
- Potential market shifts due to technological advancements in treatments.
- Changes in regulatory environments affecting market access.
- Impacts of demographic changes and lifestyle shifts on product demand.
- Emerging competition and innovation within the healthcare sector.
